Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05676385
Other study ID # SBB22R&52507
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date February 13, 2023
Est. completion date March 30, 2023

Study information

Verified date June 2023
Source Nutricia Research
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study assesses the glycemic responses to several nutritional products.


Description:

During a study visit fasted subjects will consume one serving of the reference product or of the test products. Venous blood samples will be taken at baseline and at several time-points over a 6-hr period.


Recruitment information / eligibility

Status Completed
Enrollment 18
Est. completion date March 30, 2023
Est. primary completion date March 30, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 50 Years
Eligibility Inclusion Criteria: 1. Healthy individuals, 18 up to and including 50 years of age. 2. Willing to maintain habitual diet, physical activity pattern, and body weight throughout the trial. 3. Willing to avoid the consumption of alcohol, unusual food intake, unusual physical activity 24h prior to each study visit. 4. Willing to come to the study visit in the morning after an overnight fast of minimum 10 hours and maximum 14 hours (with water only). Exclusion Criteria: 1. Blood glucose levels = 7.8 mmol/L at screening (not fasted) 2. Known history of gastrointestinal disease (e.g., diverticulitis, Crohn's disease, coeliac disease etc.), bariatric surgery, AIDS, hepatitis, a history or presence of clinically important endocrine (including Type 1 or Type 2 diabetes mellitus), or any condition which might, in the opinion of the Principal Investigator either: 1) make participation dangerous to the subject (e.g. anaemia) or to others, or 2) affect the results. 3. Use of medications known to influence carbohydrate metabolism, gastrointestinal function or appetite, including, but not limited to adrenergic blockers, diuretics, thiazolidinediones, metformin and systemic corticosteroids within 4 weeks of the screening visit, or any medication which might, in the opinion of the Principal Investigator either: 1) make participation dangerous to the subject or to others, or 2) affect the results. 4. Use of medications known to influence gastric emptying (including but not limited to anticholinergics, nicotine, narcotic analgesics, ganglion blocking drugs, antacids and metoclopramide). 5. Use of anti-clotting medications. 6. Current tobacco smokers or smokers that quite smoking < 1 month prior to screening (except for occasional (= 3) cigarettes/cigars/pipes per week on average over the past month). 7. Self-reported pregnancy or breastfeeding

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
First concept product (containing 50 grams of carbohydrates)
Fasted intake of First concept product (randomised)
Second concept product (containing 50 grams of carbohydrates)
Fasted intake Second concept product (randomised)
Reference product (containing 50 grams of carbohydrates)
Fasted intake of Reference product (randomised)

Locations

Country Name City State
Netherlands EB UtrechtResearch BV Utrecht

Sponsors (1)

Lead Sponsor Collaborator
Nutricia Research

Country where clinical trial is conducted

Netherlands, 

Outcome

Type Measure Description Time frame Safety issue
Primary Decline in glucose level after reaching peak (Cmax) The decline in glucose (mmol/hour) after reaching peak glucose levels (Cmax) until reaching baseline (t = -5) blood glucose levels or, in case baseline blood glucose levels are not reached, the lowest observed blood glucose level. 6 hours
Secondary Incremental Area Under the Curve (iAUC) for glucose Incremental Area Under the Curve (iAUC) for glucose (mmol/L/hrs) 6 hours
Secondary Incremental Area Under the Curve (iAUC) for insulin Incremental Area Under the Curve (iAUC) for insulin (pmol/L/hrs) 6 hours
Secondary Incremental Area Under the Curve (iAUC) for paracetamol Incremental Area Under the Curve (iAUC) for paracetamol (pmol/L/hrs) 6 hours
Secondary Incremental peak levels (iCmax) of glucose Incremental peak levels (iCmax) of glucose (mmol/L) 6 hours
Secondary Incremental peak levels (iCmax) of insulin Incremental peak levels (iCmax) of insulin (pmol/L) 6 hours
Secondary Incremental peak levels (iCmax) of paracetamol Incremental peak levels (iCmax) of paracetamol (mg/L) 6 hours
Secondary Time to peak levels (Tmax) of glucose Time to peak levels (Tmax) of glucose (min) 6 hours
Secondary Time to peak levels (Tmax) of insulin Time to peak levels (Tmax) of insulin (min) 6 hours
Secondary Time to peak levels (Tmax) of paracetamol Time to peak levels (Tmax) of paracetamol (min) 6 hours
See also
  Status Clinical Trial Phase
Completed NCT03984370 - Dasiglucagon in the Treatment of Postprandial Hypoglycaemia After Roux-en-Y Gastric Bypass Phase 2
Completed NCT03200782 - Postprandial Hypoglycemia in Patients After Bariatric Surgery With Empagliflozin and Anakinra - The Hypo-BEAR-Study N/A
Recruiting NCT05036317 - Empagliflozin for the Treatment of Postprandial Hypoglycemia Phase 3
Active, not recruiting NCT05174507 - Empagliflozin and Anakinra for the Treatment of Postprandial Hypoglycemia in Patients With Prediabetes Phase 2
Completed NCT04330196 - Effect of Postprandial Hyperinsulinaemic Hypoglycaemia on Driving Performance. N/A
Recruiting NCT04720859 - Canagliflozin in Postprandial Hyperinsulinemic Hypoglycemia (CANA-PHH-RYGB) N/A
Completed NCT04836273 - Treatment of Post-bariatric Hypoglycaemia Phase 2
Completed NCT05513404 - The Scottish Fruit Study N/A
Completed NCT01162499 - Role of Glucagon-Like Peptide-1 in Postprandial Hypoglycemia N/A
Recruiting NCT05401578 - Canakinumab for the Treatment of Postprandial Hypoglycemia Phase 3